ストックスクリーナーアプリを入手
11.85
16.86%
1.71
前日終値:
$10.14
開ける：
$12.6
24時間の取引高:
2.21M
Relative Volume:
2.81
時価総額：
$911.93M
収益：
-
当期純損益:
$-209.96M
株価収益率:
-3.75
EPS:
-3.16
ネットキャッシュフロー:
$-176.27M
1週間 パフォーマンス:
+12.96%
1か月 パフォーマンス:
-5.12%
6か月 パフォーマンス:
+19.82%
1年 パフォーマンス:
+57.58%
1日の値動き範囲:
$11.48
$13.13
1週間の範囲:
$10.05
$13.13
52週間の値動き範囲:
$4.92
$17.00
Replimune Group Inc Stock (REPL) Company Profile
REPL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
11.85 | 911.93M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-04-17 | 再開されました | Piper Sandler | Overweight |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-17 | 開始されました | BTIG Research | Buy |
| 2020-11-02 | 開始されました | Jefferies | Buy |
| 2020-10-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-09-04 | 開始されました | ROTH Capital | Buy |
| 2019-07-23 | 開始されました | Chardan Capital Markets | Buy |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-25 | 開始されました | Wedbush | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 開始されました | JP Morgan | Overweight |
| 2018-08-14 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Replimune Group Inc (REPL) 最新ニュース
Barclays maintains Replimune stock with $17 target By Investing.com - Investing.com UK
Replimune stock soars on FDA priority review for melanoma treatment - MSN
Replimune stock price target raised to $27 by BMO Capital - Investing.com South Africa
Replimune Stock Soars 16% on FDA Priority Review for Advanced Me - GuruFocus.com
Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy - Yahoo Finance
Replimune stock soars on FDA priority review for melanoma treatment By Investing.com - Investing.com Australia
Replimune Group (NASDAQ:REPL) Shares Gap UpTime to Buy? - MarketBeat
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga
FDA accepts Replimune's advanced melanoma therapy BLA - Investing.com
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma - The Manila Times
FDA Grants Priority Review to Replimune's Melanoma Treatment RP1, Breakthrough Therapy Status Secured - StockTitan
JPMorgan Chase & Co. Raises Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Trend Tracker for (REPL) - Stock Traders Daily
Replimune's SWOT analysis: biotech firm's stock poised for growth in oncology - MSN
Replimune Group (NASDAQ:REPL) Trading Down 6.6%Here's Why - MarketBeat
Barclays PLC Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Barclays PLC Has $1.74 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Replimune Awards Equity Incentives to 30 New Hires, Including 253,820 Shares in Options and RSUs - StockTitan
Replimune Group Inc (REPL-Q) QuotePress Release - The Globe and Mail
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials - The Manila Times
Replimune Launches Two Major Clinical Trials for Melanoma and Liver Cancer Treatment RP2 - StockTitan
Replimune Group, Inc. (NASDAQ:REPL) Receives $17.29 Consensus PT from Brokerages - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Up 9.5%What's Next? - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Increases Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Geode Capital Management LLC Acquires 217,308 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune's stock surges 19% after-hours on FDA BLA submission - MSN
Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Barclays PLC - Defense World
Replimune Group to Present at J.P. Morgan Healthcare Conference: Key Biotech Updates Coming - StockTitan
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
State Street Corp Buys 1,182,181 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Jane Street Group LLC Sells 274,078 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading 8.2% HigherTime to Buy? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,759 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Insider Selling: Replimune Group, Inc. (NASDAQ:REPL) CEO Sells 10,000 Shares of Stock - MarketBeat
Replimune CEO Sushil Patel sells $124,200 in company stock - Investing.com
Replimune CEO Sushil Patel sells $124,200 in company stock By Investing.com - Investing.com Australia
Wellington Management Group LLP Decreases Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
BNP Paribas Financial Markets Buys 6,748 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading Down 4.7%Here's Why - MarketBeat
Replimune management to meet with Jefferies - Nasdaq
When (REPL) Moves Investors should Listen - Stock Traders Daily
Replimune's SWOT analysis: biotech's melanoma treatment stock nears key milestones By Investing.com - Investing.com South Africa
Replimune's SWOT analysis: biotech's melanoma treatment stock nears key milestones - Investing.com India
Replimune Group Inc (REPL) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):